Selected recent randomized trials testing therapies in patients with limited-stage Hodgkin’s lymphoma.
| Author . | Control Group Therapy . | Experimental Group Therapy . | Number Evaluated . | Disease Control Outcome* . | Overall Survival* . |
|---|---|---|---|---|---|
| * Results reported for experimental group followed by control group | |||||
| Abbreviations: EF RT, extended-field radiation; IF RT, involved-field radiation; CMT, combined modality therapy; ABVD, doxorubicin (Adriamycin®), bleomycin, vinblastine, dacarbazine; AV, doxorubicin (Adriamycin), vinblastine; MOPP-ABV, mechlorethamine, vincristine (Oncovin®), prednisone, procarbazine, doxorubicin (Adriamycin), bleomycin, vinblastine; CR, complete response; FFTF, freedom from treatment failure; FFS, failure-free survival; FFP, freedom from progression; ns, not stated | |||||
| Sieber3 | EF RT | CMT: 2 ABVD + EF RT | 571 | 2-yr FFTF: 96% vs 84%; P < 0.05 | 2-yr: 98% vs 98%; P = ns |
| Press11 | EF RT | CMT: 3 AV + EF RT | 326 | 3-yr FFS: 94% vs 81%; P < 0.001 | 3-yr: both > 95%; P = ns |
| Hagenbeek12 | EF RT | CMT: 3 MOPP-ABV + IF RT | 543 | 4-yr FFS: 99% vs 77%; P < 0.001 | 4-yr: 99% vs 95%; P = 0.019 |
| Meyer4 | EF RT (favorable cohort) or CMT (unfavorable cohort): 2 ABVD + EF RT | ABVD: 4 cycles if CR after 2 cycles 6 cycles if no CR after 2 cycles | 399 | 5-yr FFP: 87% vs 93%; P = 0.006 | 5-yr: 96% vs 94%; P = 0.4 |
| Author . | Control Group Therapy . | Experimental Group Therapy . | Number Evaluated . | Disease Control Outcome* . | Overall Survival* . |
|---|---|---|---|---|---|
| * Results reported for experimental group followed by control group | |||||
| Abbreviations: EF RT, extended-field radiation; IF RT, involved-field radiation; CMT, combined modality therapy; ABVD, doxorubicin (Adriamycin®), bleomycin, vinblastine, dacarbazine; AV, doxorubicin (Adriamycin), vinblastine; MOPP-ABV, mechlorethamine, vincristine (Oncovin®), prednisone, procarbazine, doxorubicin (Adriamycin), bleomycin, vinblastine; CR, complete response; FFTF, freedom from treatment failure; FFS, failure-free survival; FFP, freedom from progression; ns, not stated | |||||
| Sieber3 | EF RT | CMT: 2 ABVD + EF RT | 571 | 2-yr FFTF: 96% vs 84%; P < 0.05 | 2-yr: 98% vs 98%; P = ns |
| Press11 | EF RT | CMT: 3 AV + EF RT | 326 | 3-yr FFS: 94% vs 81%; P < 0.001 | 3-yr: both > 95%; P = ns |
| Hagenbeek12 | EF RT | CMT: 3 MOPP-ABV + IF RT | 543 | 4-yr FFS: 99% vs 77%; P < 0.001 | 4-yr: 99% vs 95%; P = 0.019 |
| Meyer4 | EF RT (favorable cohort) or CMT (unfavorable cohort): 2 ABVD + EF RT | ABVD: 4 cycles if CR after 2 cycles 6 cycles if no CR after 2 cycles | 399 | 5-yr FFP: 87% vs 93%; P = 0.006 | 5-yr: 96% vs 94%; P = 0.4 |